// App-Quantinova.ai

: Randomized Phase 2 Study of Nintedanib with or Without Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Who Experienced a Clinically Meaningful Decline in Forced Vital Capacity During Prior Pirfenidone Administration

Researchers

Presenter

  • S. Ikeda

Principal Investigators

  • A. Sekine

  • T. Baba

  • T. Katano

  • E. Tabata

  • R. Shintani

  • H. Yamakawa

  • T. Oda

  • R. Okuda

  • H. Kitamura

  • T. Iwasawa

  • T. Takemura

  • T. Ogura

Medical Centers

  • Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan

  • Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan

  • Department of Surgical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Single Center

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved